About Ozempic®
Class: Brand semaglutide for T2D
Brand/Manufacturer: Novo Nordisk
Dosing: Weekly subcutaneous (0.25-2.0 mg)
Mean weight loss: See SUSTAIN
Pivotal trial: SUSTAIN-1 through SUSTAIN-7
Ozempic® is Novo Nordisk's brand-name semaglutide approved for type 2 diabetes. Off-label use for weight loss is common. Retail price $935-$969/month without insurance. SUSTAIN-6 demonstrated 26% reduction in major cardiovascular events in T2D patients.
Mechanism of action
Ozempic® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is See SUSTAIN body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Ozempic®'s weight management indication is SUSTAIN-1 through SUSTAIN-7. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Ozempic® via telehealth
Ozempic® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Ozempic® access — see the side panel for details.
FAQ
Is Ozempic® FDA-approved?
The brand-name versions of Ozempic® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Ozempic® cost?
Brand-name Ozempic® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.